Several African countries are increasingly wary of accepting health aid packages from the Trump administration, signaling a shift in how foreign assistance is perceived on the continent. While the U.S. government frames its aid as a strategic investment to build self-reliant health systems, many African nations see the new model as transactional and laden with conditions that prioritize American economic and political interests over genuine partnership.
A New Model of Aid: From Charity to Transaction
Under President Donald Trump, U.S. foreign assistance has undergone a fundamental transformation. The traditional approach—often mediated through organizations like USAID or the World Health Organization (WHO)—has been replaced by direct bilateral agreements with African governments. This shift is designed to reduce dependency on NGOs and parallel delivery systems, with the U.S. expecting recipient countries to increase their own health spending as a sign of commitment.
For example, Kenya’s landmark $2.5 billion health deal, signed last December, includes $1.6 billion from the U.S. and $850 million pledged by Kenya over five years. Yet, even this flagship agreement has faced legal challenges and delays, illustrating the friction caused by the new terms.
Concerns Over Data Sovereignty and Commercial Ties
One of the most contentious aspects of the Trump administration’s health MOUs is the requirement for African countries to share health data and biological samples—pathogens that cause diseases—with U.S. authorities and pharmaceutical companies. Ghana, Zimbabwe, and Zambia have all expressed reservations about this arrangement, citing concerns over data protection and sovereignty.
Ghana’s Data Protection Commission highlighted the lack of reciprocal protections for Ghanaian data once it leaves the country’s borders. Zimbabwe also rejected a deal over fears that the U.S. would gain access to medical data without guarantees that resulting treatments or vaccines would be made available to its population. These concerns are compounded by the U.S. insistence on prioritizing American pharmaceutical firms in developing and delivering treatments, effectively tying aid to commercial benefits for the U.S.
Strategic and Political Strings Attached
The Trump administration’s “America First” policy explicitly frames foreign aid as a tool to advance U.S. strategic and commercial interests rather than as unconditional humanitarian support. Zambia’s Foreign Minister Mulambo Haimbe criticized attempts to link health funding to U.S. access to critical minerals, demanding that these issues be negotiated separately rather than as a package deal.
South Africa’s recent exclusion from U.S. HIV/AIDS funding after failing to meet certain “policy requests” further illustrates the hardline stance. These requests reportedly included politically sensitive issues, such as the treatment of the white-minority Afrikaner community, a move that drew widespread criticism and accusations of racial bias.
Impact on Regional Health Security and Response
The new bilateral approach raises questions about the effectiveness and sustainability of health responses in Africa. The Democratic Republic of Congo (DR Congo), one of the first to sign the U.S. health deal, is currently battling a new Ebola outbreak. While the U.S. claims its agreement has helped coordinate the response, humanitarian organizations report that previous USAID funding cuts severely weakened frontline efforts, resulting in delayed detection and inadequate preparedness.
Experts warn that bilateral deals risk fragmenting global health cooperation. Infectious diseases do not respect borders, and effective responses require multilateral coordination—something the Trump administration’s withdrawal from the WHO and reliance on direct country-to-country agreements undermine.
Africa’s Growing Assertiveness in Health Diplomacy
African countries are increasingly asserting their right to shape health partnerships on their own terms. The continent’s experience during the COVID-19 pandemic, where it struggled to access vaccines despite sharing pathogen data, has heightened sensitivity to exploitative arrangements. Civil society groups and several governments have voiced opposition to U.S. terms that appear to prioritize American interests over African health security.
South Africa’s Health Minister notably condemned the U.S. demand for pathogen access as a form of “genome for life” extraction in exchange for limited funding, emphasizing that no self-respecting nation should accept such conditions.
Looking Ahead: Balancing Aid and Autonomy
The Trump administration’s redefinition of foreign aid as a strategic, transactional tool presents a challenge for African nations seeking to improve health outcomes without compromising sovereignty. While increased domestic investment in health is a positive goal, the conditionality and commercial prioritization embedded in these deals risk alienating key partners and undermining trust.
For the U.S., maintaining global health leadership will require navigating the fine line between advancing national interests and fostering genuine, equitable partnerships. For African countries, the moment is one of reckoning: how to leverage critical support while safeguarding autonomy and ensuring that health aid serves the continent’s long-term needs rather than short-term geopolitical calculations.
Recommended reading
For more context, see related Peack News coverage and explainers linked below.